


Supplementary Figure 1. *NPM1* VAF distribution across all patients

Supplementary Figure 1

Supplementary Table 1. Demographic and clinical characteristics of the entire population (N=147)

	N (%)	Mutant <i>NPM1</i> VAF (%) Median [IQR]	P value
Gender			
Female	88 (60%)	43.5 [37.0-48.3]	p=0.96
Male	59 (40%)	43.6 [37.2-47.2]	
Age (years)			
<60	125 (85%)	43.8 [37.2-48.0]	p=0.40
≥60	22 (15%)	41.0 [35.3-47.9]	
<i>FLT3</i>-ITD Mutation			
No	78 (53%)	42.0 [34.8-46.9]	p=0.03
Yes	69 (47%)	45.0 [39-48.8]	
<i>DNMT3A</i> Mutation			
No	58 (64%)	42.0 [37.0-47.1]	p=0.19
Yes	33 (36%)	45.0 [37.5-49]	
<i>NPM1</i> VAF Method			
Capillary electrophoresis	63 (43%)	45.6 [37.3-47.9]	p=0.36
NGS	84 (57%)	42.0 [37.0-48.0]	
Treatment*			
IA	50 (34%)	44.0 [37.2-47.9]	p=0.87**
CIA	44 (30%)	43.6 [36.2-47.0]	
CLIA	35 (25%)	45.0 [37.5-49.0]	
FIA	16 (11%)	41.5 [35.8-43.2]	
Cytogenetics			
Diploid	122 (83%)	43.8 [37.5-48.0]	p=0.08***
ACA	20 (14%)	40.8 [32.0-45.5]	
Insufficient metaphases/not done	5 (4%)	33.0 [30.0-36.0]	

NGS=next-generation sequencing; IA=idarubicin, cytarabine; CIA=clofarabine, idarubicin, cytarabine; CLIA=cladribine, idarubicin, cytarabine; FIA=fludarabine, idarubicin, cytarabine; ACA = additional chromosomal abnormalities; VAF=variant allele frequency; IQR=interquartile range

p value for Student's t-test of mutant *NPM1* VAF with respect to the categories, unless otherwise noted

*54 patients received a *FLT3* inhibitor in addition to chemotherapy; 22 patients received an additional investigational agent

** P value based on one-way ANOVA test among all 4 treatments

***P value refers only to diploid versus ACA